Smooth vs textured breast implants: what actually changes?
Smooth and textured describe an implant's shell surface, not fill, shape, size, profile, or pocket. FDA says BIA-ALCL risk is higher with textured implants than smooth implants. Verify the exact model, current availability, labeling, device history, placement, surveillance, and revision plan.
Smooth and textured describe a breast implant’s outer shell surface—not its saline or silicone fill, shape, size, profile, or pocket. Surface can affect tissue interaction and is central to the BIA-ALCL discussion; FDA says BIA-ALCL risk is higher with textured implants than with smooth implants. Verify the exact model, current labeling and availability, device history, placement, surveillance, and revision plan.12
A useful comparison keeps each implant variable on its own line. “Teardrop silicone,” for example, combines shape and fill but still does not identify surface, dimensions, manufacturer or model.
Decompose the implant name
| Variable | Examples | Question it answers |
|---|---|---|
| Shell surface | Smooth or a product-specific texture | How the outside of the implant is manufactured and identified |
| Fill | Saline or silicone gel with product-specific formulation | What is inside the shell and how rupture may present |
| Shape | Round or shaped/anatomic | How dimensions and orientation are designed |
| Dimensions | Width, height, projection and volume | How the exact device fits a tissue and pocket plan |
| Over or under muscle and other surgical variations | Where the surgeon plans to place the device |
FDA’s implant-type page lists surface texture as one characteristic among fill, shape and profile.1 Do not infer that smooth means saline, textured means silicone, or a particular surface dictates one pocket.
Put BIA-ALCL in a product-specific record
Breast implant-associated anaplastic large cell lymphoma is a lymphoma that usually involves the fluid or capsule around an implant rather than breast tissue itself. FDA states that risk is higher for textured-surface implants than for smooth-surface implants.2 Surface history therefore matters even if a person does not know the fill or if implants have been exchanged.
Record every implant and tissue expander over time: manufacturer, product, surface, dimensions, lot and serial, side, placement and removal dates, and whether the capsule was sampled. Symptoms such as persistent swelling, a mass or pain around an implant require clinical evaluation; they should not be self-classified from surface alone.2 The BIA-ALCL and capsule-SCC guide separates symptom, fluid, imaging and pathology records.
FDA’s 2019 action concerned specific Allergan BIOCELL textured implant and tissue-expander models, not every breast implant made by every manufacturer.4 FDA did not recommend routine removal of those devices in patients without symptoms at that time because of the potential risks of surgery.4 That dated recommendation should not be turned into individual advice or applied to a different device without current clinical review.
Current availability is not the same as implant history
A model no longer offered for new surgery may remain implanted. A practice that currently uses only smooth implants still needs to identify a patient’s earlier devices. Conversely, a product brochure or overseas availability does not establish current FDA approval and commercial availability in the United States.
Use FDA’s approved-implant labeling page to find current manufacturer booklets and approval materials for the candidate device.3 Then compare the sealed implant and stickers with the plan. The UDI and device-card guide explains how model, device identifier, lot and serial serve different follow-up jobs.
Surface does not decide the entire operation
The surgical plan still includes tissue thickness, breast dimensions, chest-wall asymmetry, incision, pocket, soft-tissue coverage, implant dimensions, nipple and fold relationship, prior surgery, reconstruction context, and what happens if the device rotates, shifts, becomes visible, ripples, contracts or requires removal.
Ask the surgeon which claimed benefit depends on surface and what evidence supports it for the exact model and operation. “Stays in place better” or “feels more natural” is too broad without product, shape, pocket, tissue and comparator.
Connect the checklist to the device card
FDA’s labeling framework includes a boxed warning, patient decision checklist, patient booklet and device card.5 The decision-checklist guide explains how to match those documents. Surface should appear consistently across the proposed model, checklist discussion, implant stickers, operative report and post-surgery card.
- Name every variable. Record manufacturer, product family, surface, fill, shape, dimensions, profile, and approval record separately.
- Open current labeling. Review the exact patient booklet, boxed warning, decision checklist, indications, contraindications, risks, and surveillance information.
- Build the device history. Collect prior cards, stickers, operative reports, exchange or removal records, capsule pathology, and imaging.
- Map the operation. Connect surface and device choice to incision, pocket, tissue coverage, fixation or orientation, follow-up, and revision pathways.
- Close the loop. After surgery, reconcile the implanted model and surface across the device card, stickers, bill, and operative report.
The decisive question is: “What is the exact implant surface and model, why is it part of this operation, and can its current labeling and complete device history be verified?”
Sources
- U.S. Food and Drug Administration. Types of Breast Implants. Used to separate shell surface, fill, shape, profile, and other implant characteristics. Accessed .
- U.S. Food and Drug Administration. Questions and Answers about BIA-ALCL. Used for FDA's current surface-risk statement, symptoms, evaluation context, and guidance for people without symptoms. Accessed .
- U.S. Food and Drug Administration. Labeling for Approved Breast Implants. Used for product-specific approval and current manufacturer labeling verification. Accessed .
- U.S. Food and Drug Administration. FDA requests Allergan recall certain textured breast implants and tissue expanders. Used for the product-specific 2019 recall, model scope, and FDA's recommendation regarding asymptomatic removal at that time. Accessed .
- U.S. Food and Drug Administration. Breast Implants—Certain Labeling Recommendations to Improve Patient Communication. Used for current labeling, decision-checklist, boxed-warning, and device-card framework. Accessed .